Pfizer to present new tofacitinib data at 11th Congress of ECCO

Pfizer announced today that it will be presenting new data based on the research of tofacitinib in ulcerative colitis (UC) and Crohn’s disease at the 11th Congress of the European Crohn's and Colitis Organisation (ECCO), which is scheduled for March 16-19 in Amsterdam.

The data being presented will include the results from two Phase 3 studies from its program called Oral Clinical Trials for tofacitinib in ulcerative colitis (OCTAVE). Tofacitinib is currently being researched as a treatment for adults who have moderate to severe active UC.

The data that will be presented at the ECCO will include a look at the Phase 3 randomized trial that studied the efficiency and safety of tofacitinib as a therapy for patients who have moderate to severe UC, the reports on patient outcomes in regards to the Phase 3 trial, and the analysis of exposure response to tofacitinib. The same topics will be covered when looking at the phase 2b trial of tofacitinib in relation to Crohn’s disease.